Ayrmid Pharma Company Profile
✉ Email this page to a colleague
What is the competitive landscape for AYRMID PHARMA
AYRMID PHARMA has one approved drug.
There are two US patents protecting AYRMID PHARMA drugs.
Drugs and US Patents for Ayrmid Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ayrmid Pharma | APHEXDA | motixafortide acetate | POWDER;SUBCUTANEOUS | 217159-001 | Sep 8, 2023 | RX | Yes | Yes | 12,268,725 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Ayrmid Pharma | APHEXDA | motixafortide acetate | POWDER;SUBCUTANEOUS | 217159-001 | Sep 8, 2023 | RX | Yes | Yes | 12,257,285 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Ayrmid Pharma | APHEXDA | motixafortide acetate | POWDER;SUBCUTANEOUS | 217159-001 | Sep 8, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Ayrmid Pharma | APHEXDA | motixafortide acetate | POWDER;SUBCUTANEOUS | 217159-001 | Sep 8, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Ayrmid Pharma Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 3205658 | ⤷ Start Trial |
| Japan | 2024501709 | ⤷ Start Trial |
| Israel | 304159 | ⤷ Start Trial |
| Mexico | 2023007867 | ⤷ Start Trial |
| Australia | 2021412499 | ⤷ Start Trial |
| European Patent Office | 4271402 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

